Michael Urban Callaghan
Central Michigan University
H-index: 31
North America-United States
Top articles of Michael Urban Callaghan
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center | Pediatric blood & cancer | Monica L Hulbert Deepa Manwani Emily Riehm Meier Ofelia A Alvarez R Clark Brown | 2023/1 |
Effects of PK‐guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A | Haemophilia | Guy Young Michael U Callaghan Vinod Balasa Amit Soni Sanjay Ahuja | 2023/9 |
5610823 TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1B CROSSWALK-A TRIAL EVALUATING THE SAFETY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE … | HemaSphere | P Bartolucci KI Ataga M Callaghan L De Franceschi C Minniti | 2023/4/1 |
5612539 TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A CROSSWALK-C TRIAL EVALUATING THE EFFICACY OF CROVALIMAB AS ADJUNCT TREATMENT IN THE … | HemaSphere | M Callaghan KI Ataga L De Franceschi C Minniti N Balachandran | 2023/4/1 |
Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A | New England Journal of Medicine | Johnny Mahlangu Radoslaw Kaczmarek Annette Von Drygalski Susan Shapiro Sheng-Chieh Chou | 2023/2/23 |
Objectives and endpoints | Presented at the 17th Annual Scientific Conference on Sickle Cell and Thalassaemia| January | Michael U Callaghan Kenneth I Ataga MD Lucia De Franceschi MD Caterina Minniti MD Nadiesh Balachandran MD | 2022 |
Prophylactic hydroxyurea treatment is associated with improved cerebral hemodynamics as a surrogate marker of stroke risk in sickle cell disease: a retrospective comparative … | Journal of Clinical Medicine | Brian R Peine Michael U Callaghan Joseph H Callaghan Alexander K Glaros | 2022/6/17 |
Results from the single and multiple ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AG-946 in healthy volunteers | Blood | Xiaoshu Dai Gurov Elizabeth Merica Varsha Iyer Annie Claeys Spurthi Patil | 2022/11/15 |
P120: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A CROSSWALK-C TRIAL EVALUATING THE EFFICACY OF CROVALIMAB AS ADJUNCT TREATMENT IN THE … | HemaSphere | M Callaghan K Ataga L De Franceschi C Minniti N Balachandran | 2022/1/1 |
Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A | Human gene therapy | Robert Klamroth Gregory Hayes Tatiana Andreeva Keith Gregg Takashi Suzuki | 2022/4/1 |
Early stage clinical trials for the treatment of hemophilia A | Gianna M Guzzardo Robert Sidonio Jr Michael U Callaghan Katherine Regling | 2022/11/2 | |
P119: trial in progress: the randomized, double-blind, placebo-controlled phase 1B CROSSWALK-A trial evaluating the safety of Crovalimab for the management of acute … | HemaSphere | P Bartolucci K Ataga M Callaghan L De Franceschi C Minniti | 2022/1/1 |
Valoctocogene roxaparvovec gene therapy for hemophilia A | New England Journal of Medicine | Margareth C Ozelo Johnny Mahlangu K John Pasi Adam Giermasz Andrew D Leavitt | 2022/3/17 |
Validation of patient‐reported vaso‐occlusive crisis day as an endpoint in sickle cell disease studies | European Journal of Haematology | Karin S Coyne Brooke M Currie Michael Callaghan Kathleen W Wyrwich Sheryl Pease | 2022/9 |
Managing severe hemophilia a in children: pharmacotherapeutic options | Katherine Regling Michael U Callaghan Robert Sidonio Jr | 2022/2/15 | |
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3 | Research and Practice in Thrombosis and Haemostasis | Michael U Callaghan Elina Asikanius Michaela Lehle Johannes Oldenburg Johnny Mahlangu | 2022/8/1 |
Longitudinal assessment of adhesion to vascular cell adhesion molecule‐1 at steady state and during vaso‐occlusive crises in sickle cell disease | British Journal of Haematology | Jennell White Michael U Callaghan Xiufeng Gao Ke Liu Ahmar Zaidi | 2022/2 |
Targeting TRPV1 activity via high‐dose capsaicin in patients with sickle cell disease | EJHaem | Alexander K Glaros Michael U Callaghan Wally R Smith Ahmar U Zaidi | 2022/8 |
Reversible cerebral vasoconstriction syndrome and sickle cell disease: a case report | Journal of Pediatric Hematology/Oncology | Katherine Regling Daniel Pomerantz Sandra Narayanan Deniz Altinok Lalitha Sivaswamy | 2021/1/1 |
Phase 1 single and multiple ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AG-946 in healthy volunteers | Blood | Varsha Iyer Elizabeth Merica Sebastien Ronseaux Tressa Gamache Nancy J Mulrow | 2021/11/23 |
Co-Authors
